Dr. Smith Uses Case Studies to Discuss Diagnostic Certainty

In this episode, Dr. Smith delves into two case studies, including one patient with cold urticaria and one with a history of asthma, and describes how the comprehensive BIOFIRE® Respiratory Panel gave him the diagnostic certainty to provide the correct treatment to his patients.

This podcast was sponsored by bioMerieux.

More about the power of PCR diagnostic testing in point-of-care clinics here.

This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.